149 related articles for article (PubMed ID: 27847447)
1. Ursodeoxycholic acid lowers bile lithogenicity by regulating SCP2 expression in rabbit cholesterol gallstone models.
Cui Y; Li Z; Zhao E; Zhang J; Cui N
EXCLI J; 2012; 11():593-603. PubMed ID: 27847447
[No Abstract] [Full Text] [Related]
2. The effect of ursodeoxycholic acid on the relative expression of the lipid metabolism genes in mouse cholesterol gallstone models.
Fan N; Meng K; Zhang Y; Hu Y; Li D; Gao Q; Wang J; Li Y; Wu S; Cui Y
Lipids Health Dis; 2020 Jul; 19(1):158. PubMed ID: 32615989
[TBL] [Abstract][Full Text] [Related]
3. Increased bile lithogenicity by SCP2 via HMGCR and CYP7A1 regulation in human hepatocytes.
Yunfeng C; Zhonglian L; Erpeng Z; Ju Z; Naiqiang C
Turk J Gastroenterol; 2013; 24(3):241-50. PubMed ID: 24226717
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Sterol Carrier Protein 2 in patients with hereditary cholesterol gallstones.
Cui Y; Li Z; Zhao E; Jia Y; Li D; Zhang J; Cui N
BMC Gastroenterol; 2011 Feb; 11():10. PubMed ID: 21310066
[TBL] [Abstract][Full Text] [Related]
5. Protective Effects of Yinchenhao Decoction on Cholesterol Gallstone in Mice Fed a Lithogenic Diet by Regulating LXR, CYP7A1, CYP7B1, and HMGCR Pathways.
Meng Y; Meng K; Zhao X; Li D; Gao Q; Wu S; Cui Y
Evid Based Complement Alternat Med; 2018; 2018():8134918. PubMed ID: 30310412
[TBL] [Abstract][Full Text] [Related]
6. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy.
Tazuma S; Kajiyama G; Mizuno T; Yamashita G; Miura H; Kajihara T; Hattori Y; Miyake H; Nishioka T; Hyogo H; Sunami Y; Yasumiba S; Ochi H; Matsumoto T; Abe A; Adachi K; Omata F; Ueno F; Sugata F; Ohguri S; Shibata H; Kokubu S
J Clin Gastroenterol; 1998 Jun; 26(4):287-91. PubMed ID: 9649013
[TBL] [Abstract][Full Text] [Related]
7. Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.
Okamoto S; Nakano K; Kosahara K; Kishinaka M; Oda H; Ichimiya H; Chijiiwa K; Kuroki S
J Gastroenterol; 1994 Feb; 29(1):47-55. PubMed ID: 8199696
[TBL] [Abstract][Full Text] [Related]
8. Bile lithogenicity and gallbladder emptying in patients with microlithiasis: effect of bile acid therapy.
Sharma BC; Agarwal DK; Dhiman RK; Baijal SS; Choudhuri G; Saraswat VA
Gastroenterology; 1998 Jul; 115(1):124-8. PubMed ID: 9649467
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis.
Lee EJ; Kim MH; Kim YR; Park JW; Park WJ
Int J Mol Med; 2018 Mar; 41(3):1715-1723. PubMed ID: 29286073
[TBL] [Abstract][Full Text] [Related]
10. Sterol carrier protein 2 participates in hypersecretion of biliary cholesterol during gallstone formation in genetically gallstone-susceptible mice.
Fuchs M; Lammert F; Wang DQ; Paigen B; Carey MC; Cohen DE
Biochem J; 1998 Nov; 336 ( Pt 1)(Pt 1):33-7. PubMed ID: 9806881
[TBL] [Abstract][Full Text] [Related]
11. Dietary fat and gut microbiota interactions determine diet-induced obesity in mice.
Kübeck R; Bonet-Ripoll C; Hoffmann C; Walker A; Müller VM; Schüppel VL; Lagkouvardos I; Scholz B; Engel KH; Daniel H; Schmitt-Kopplin P; Haller D; Clavel T; Klingenspor M
Mol Metab; 2016 Dec; 5(12):1162-1174. PubMed ID: 27900259
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of sterol carrier protein-2 mRNA in patients with cholesterol gallstones.
Cui NQ; Zhang SK; Cui YF; Li DH; Chen C; Wu XZ
Hepatobiliary Pancreat Dis Int; 2005 Feb; 4(1):117-20. PubMed ID: 15730934
[TBL] [Abstract][Full Text] [Related]
13. Triglycerides and gallstone formation.
Smelt AH
Clin Chim Acta; 2010 Nov; 411(21-22):1625-31. PubMed ID: 20699090
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol metabolism in human gallbladder mucosa: relationship to cholesterol gallstone disease and effects of chenodeoxycholic acid and ursodeoxycholic acid treatment.
Sahlin S; Ahlberg J; Reihnér E; Ståhlberg D; Einarsson K
Hepatology; 1992 Aug; 16(2):320-6. PubMed ID: 1639340
[TBL] [Abstract][Full Text] [Related]
15. Effect of the type of dietary fat on biliary lipid composition and bile lithogenicity in humans with cholesterol gallstone disease.
Yago MD; González V; Serrano P; Calpena R; Martínez MA; Martínez-Victoria E; Mañas M
Nutrition; 2005 Mar; 21(3):339-47. PubMed ID: 15797676
[TBL] [Abstract][Full Text] [Related]
16. Long-term administration of a Niemann-Pick C1-like 1 inhibitor, ezetimibe, does not worsen bile lithogenicity in dyslipidemic patients with hepatobiliary diseases.
Kishikawa N; Kanno K; Sugiyama A; Yokobayashi K; Mizooka M; Tazuma S
J Hepatobiliary Pancreat Sci; 2016 Feb; 23(2):125-31. PubMed ID: 26692575
[TBL] [Abstract][Full Text] [Related]
17. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones.
Smith JL; Roach PD; Wittenberg LN; Riottot M; Pillay SP; Nestel PJ; Nathanson LK
J Gastroenterol Hepatol; 2000 Aug; 15(8):871-9. PubMed ID: 11022827
[TBL] [Abstract][Full Text] [Related]
18. The Syrian golden hamster strain LPN: a useful animal model for human cholelithiasis.
Combettes-Souverain MM; Souidi M; Parquet MA; Ferezou JM; Riottot MJ; Serougne CJ; Lutton CY
J Nutr Biochem; 2002 Apr; 13(4):226-236. PubMed ID: 11988405
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone prevents cholesterol gallstone formation through the regulation of cholesterol homeostasis in guinea pigs with a lithogenic diet.
Han T; Lv Y; Wang S; Hu T; Hong H; Fu Z
Lipids Health Dis; 2019 Dec; 18(1):218. PubMed ID: 31829191
[TBL] [Abstract][Full Text] [Related]
20. Effects of chenodeoxycholic and ursodeoxycholic acids on lipid metabolism and gallstone formation in the prairie dog.
Cohen BI; Singhal AK; Stenger RJ; May-Donath P; Finver-Sadowsky J; McSherry CK; Mosbach EH
Hepatology; 1984; 4(2):300-7. PubMed ID: 6706304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
